Skip to main content
SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. logo

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. — Investor Relations & Filings

Ticker · 688238 ISIN · CNE1000059N9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 486 across all filing types
Latest filing 2023-05-16 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688238

About SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD.

https://www.obio-tech.com/

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. is a specialized Contract Development and Manufacturing Organization (CDMO) focused on the gene and cell therapy (GCT) sector. The company provides end-to-end solutions encompassing vector construction, process development, analytical method development, and large-scale GMP manufacturing. Its service portfolio includes the production of viral vectors such as adeno-associated virus (AAV), lentivirus, adenovirus, and oncolytic viruses, as well as plasmid DNA and cell therapy products. Obio Technology supports clients from early-stage research through clinical trials to commercialization. The company operates advanced facilities designed to meet international regulatory standards, facilitating the development of innovative genetic medicines and advanced therapies for global biopharmaceutical partners.

Recent filings

Filing Released Lang Actions
上海市金茂律师事务所关于和元生物技术（上海）股份有限公司2022年年度股东大会之法律意见书
Regulatory Filings
2023-05-16 Chinese
2022年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2022 Annual General Meeting (AGM) of 和元生物技术（上海）股份有限公司. It includes information about the meeting date, attendance, voting results on various proposals including the 2022 annual report, financial statements, board reports, auditor appointment, profit distribution, amendments to company articles, and other governance matters. The document is not the annual report itself but the official announcement of the voting results and resolutions from the AGM. It contains detailed voting statistics and legal attestations confirming the validity of the meeting and resolutions. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and content confirm it is not a brief report publication announcement or a regulatory filing. Confidence is high due to the specificity and completeness of voting details and meeting procedural information.
2023-05-16 Chinese
海通证券股份有限公司关于和元生物技术（上海）股份有限公司2022年度持续督导现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2022年度持续督导现场检查报告" which translates to "2022 Annual Continuous Supervision On-site Inspection Report" by Haitong Securities for Heyuan Biotechnology (Shanghai) Co., Ltd. It is a detailed report of the on-site inspection conducted by the sponsor institution as part of continuous supervision during the IPO period. The content includes governance, internal control, information disclosure, independence, use of raised funds, related party transactions, and operational status. It is not an annual report (10-K), nor an audit report (AR), nor a regulatory filing (RNS) or announcement. It is a standalone inspection report related to regulatory continuous supervision and compliance, which fits the category of Audit Report / Information (AR). The document length is 3484 characters, which is sufficient for a substantive report, not a mere announcement. Therefore, the best classification is AR with high confidence. FY 2022
2023-05-08 Chinese
海通证券股份有限公司关于和元生物技术（上海）股份有限公司2022年度持续督导年度跟踪报告
Regulatory Filings Classification · 95% confidence The document is titled as a "2022年度持续督导年度跟踪报告" (2022 Annual Continuous Supervision Tracking Report) issued by Haitong Securities Co., Ltd. as the sponsor for Heyuan Biotechnology (Shanghai) Co., Ltd. It references regulatory approvals from the China Securities Regulatory Commission (CSRC) for the company's IPO and details the continuous supervision activities during 2022. The content includes detailed descriptions of supervision work, risk disclosures, financial data, compliance with regulations, and the use of raised funds. It is a comprehensive report on the sponsor's ongoing supervision of the company post-IPO, which is a regulatory requirement in China for newly listed companies. This type of document is a continuous supervision report rather than a full annual report or earnings release. It is not a simple announcement or certification but a substantive report with detailed analysis and data. Therefore, it fits best under the category of Regulatory Filings (RNS) as it is a regulatory compliance document that does not match other specific categories like Annual Report (10-K) or Interim Report (IR).
2023-05-08 Chinese
2022年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as "2022 年年度股东大会 会议资料" which translates to "2022 Annual General Meeting (AGM) Meeting Materials". It contains detailed agenda items, proposals, reports, and voting instructions related to the 2022 Annual General Meeting of 和元生物技术（上海）股份有限公司 (OBiO Technology (Shanghai) Corp., Ltd.). The content includes meeting notices, agenda, proposals for approval including annual reports, board reports, financial reports, remuneration plans, and governance amendments, all typical materials prepared and distributed for an AGM. The document is comprehensive and clearly intended as meeting materials for the AGM rather than a standalone annual report or other filing. Therefore, it fits the category of AGM Information (AGM-R).
2023-05-05 Chinese
简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the changes in shareholding by specific investors in the company 和元生物技术（上海）股份有限公司, including the reduction of shares held by the information disclosure obligors below 5%. The document includes detailed information about the shareholders, their holdings before and after the change, the method of share reduction (block trades and centralized bidding), and compliance with relevant securities laws and regulations. It is a formal report on changes in major shareholding stakes, consistent with notifications required when significant shareholders cross ownership thresholds. There is no indication that this is an announcement of a report publication, nor is it a financial report or management report. The content fits the definition of a Major Shareholding Notification (MRQ) as it reports changes in significant share ownership levels crossing thresholds (from above 5% to below 5%). The document length and detail confirm it is the report itself, not just an announcement or certification.
2023-05-04 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.